Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by WINTON GROUP Ltd

WINTON GROUP Ltd grew its holdings in Arcus Biosciences, Inc. (NYSE:RCUS) by 5.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 72,310 shares of the company’s stock after buying an additional 3,730 shares during the period. WINTON GROUP Ltd’s holdings in Arcus Biosciences were worth $1,077,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Jane Street Group LLC boosted its stake in Arcus Biosciences by 59.8% in the 3rd quarter. Jane Street Group LLC now owns 217,041 shares of the company’s stock worth $3,319,000 after purchasing an additional 81,193 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Arcus Biosciences by 11.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company’s stock worth $8,669,000 after buying an additional 59,536 shares during the last quarter. Parkman Healthcare Partners LLC lifted its stake in shares of Arcus Biosciences by 146.9% during the third quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company’s stock worth $15,684,000 after buying an additional 610,219 shares during the period. Barclays PLC grew its holdings in shares of Arcus Biosciences by 49.0% during the third quarter. Barclays PLC now owns 118,693 shares of the company’s stock valued at $1,816,000 after buying an additional 39,015 shares during the last quarter. Finally, US Bancorp DE increased its position in shares of Arcus Biosciences by 2,432.0% in the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after acquiring an additional 6,615 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Trading Down 3.8 %

Arcus Biosciences stock opened at $8.17 on Friday. The firm has a market cap of $858.45 million, a PE ratio of -2.59 and a beta of 1.36. Arcus Biosciences, Inc. has a 12 month low of $8.02 and a 12 month high of $18.98. The stock’s 50 day simple moving average is $11.11 and its two-hundred day simple moving average is $14.35. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The business had revenue of $36.00 million for the quarter, compared to analyst estimates of $29.38 million. Analysts anticipate that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RCUS has been the subject of a number of research reports. Morgan Stanley lowered their price target on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. HC Wainwright upgraded Arcus Biosciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $18.00 to $24.00 in a research report on Wednesday, February 26th. Finally, Bank of America reduced their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $30.25.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the transaction, the chief financial officer now owns 60,138 shares of the company’s stock, valued at $902,070. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Yasunori Kaneko purchased 20,000 shares of the stock in a transaction dated Thursday, February 27th. The stock was purchased at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the purchase, the director now directly owns 28,400 shares of the company’s stock, valued at approximately $285,704. The trade was a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.